Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on sleep in brain health

LIVE: Thursday 2nd May 2024, 18:00-19:30 (CEST)

Quality sleep is essential for health. But what happens to our brains when sleep patterns are disturbed? Join our experts to explore the interplay between sleep disruption and neurological diseases, and the questions that you need to be asking your patients to help you prevent the harmful effects of sleep deprivation.
ADVANCED SEARCH
Log in
Top
World Journal of Urology
Published in: World Journal of Urology 9/2020

01-09-2020 | Multiple Sclerosis | Original Article

Urinary biomarkers profiles in patients with neurogenic detrusor overactivity according to their neurological condition

Authors: Claire Richard, Claude Bendavid, Juliette Hascoet, Quentin Alimi, Zine-eddine Khene, Jacques Kerdraon, Caroline Voiry, Charlène Brochard, Guillaume Bouguen, Laurent Siproudhis, Andrea Manunta, Xavier Gamé, Benoit Peyronnet

Published in: World Journal of Urology | Issue 9/2020

Login to get access

Abstract

Objectives

The aim of this study was to investigate the disease-specific urinary levels variations of neurotrophins (NGF, BDNF), mediators of inflammation (TGFβ-1, PGE-2) and markers of extracellular matrix alterations (TIMP-2) in patients with multiple sclerosis (MS) spinal cord injury (SCI), or spina bifida (SB), and neurogenic detrusor overactivity (NDO).

Methods

A prospective single-center study was conducted between March 2015 and March 2017. Patients aged over 18 years old, with neurological disease, with a urodynamic diagnosis of NDO were included. The urinary levels of NGF, BDNF, TIMP-2, PGE 2, and TGF-β1 were measured using dedicated ELISA kits.

Results

Forty-one patients were included: 6 with MS, 20 with SCI, and 15 with spina bifida. The average urinary level of NGF/Cr was significantly higher in MS patients compared to other neurologic populations (8 vs. 0.56 vs. 1.25 pg/mg of creatinine; p = 0.001) as well for the average urinary level of BDNF (88.3 vs. 5 vs. 4.8 pg/mg of creatinine; p < 0.0001). SCI patients had a significantly lower level of TGFβ-1 than SB patients (p = 0.04). The urinary level of PGE2 was significantly correlated with the Body Mass Index (r = 0.61; p = 0.0002).

Conclusion

All NDO may not be created equal from the molecular standpoint. Multiple sclerosis patients had higher urinary levels of neurotrophins than in other neurologic populations with NDO. Urinary TGFβ-1, a strong determinant of extracellular matrix, was significantly higher in spina bifida patients compared to SCI patients. These findings underscore the importance of using and interpreting those possible urinary markers in a disease-specific fashion.
Literature
1.
Gajewski JB, Schurch B, Hamid R, Averbeck M, Sakakibara R, Agrò EF et al (2018) An International Continence Society (ICS) report on the terminology for adult neurogenic lower urinary tract dysfunction (ANLUTD). Neurourol Urodyn 37(3):1152–1161PubMedCrossRef
2.
Haab F (2014) Chapter 1: the conditions of neurogenic detrusor overactivity and overactive bladder. Neurourol Urodyn 33(Suppl 3):S2–S5PubMedCrossRef
3.
Ruffion A, de Sèze M, Denys P, Perrouin-Verbe B, Chartier-Kastler E, Groupe d’Etudes de Neuro-Urologie de Langue Française (2007) Groupe d’Etudes de Neuro-Urologie de Langue Française (GENULF) guidelines for the management of spinal cord injury and spina bifida patients. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 17(3):631–633CrossRef
4.
Decramer S, Gonzalez de Peredo A, Breuil B, Mischak H, Monsarrat B, Bascands J-L et al (2008) Urine in clinical proteomics. Mol Cell Proteom 7(10):1850–1862CrossRef
5.
Peyronnet B, Bendavid C, Manunta A, Damphousse M, Cheensse C, Brochard C et al (2015) The role of urinary markers in the assessment and follow-up of lower urinary tract disorders: a literature review. Progres En Urol J Assoc Francaise Urol Soc Francaise Urol 25(4):188–199CrossRef
6.
Top T, Sekerci CA, Isbilen-Basok B, Tanidir Y, Tinay I, Isman FK et al (2017) The effect of intradetrusor botulinum neurotoxin type A on urinary NGF, TGF BETA-1, TIMP-2 levels in children with neurogenic detrusor overactivity due to myelodysplasia. Neurourol Urodyn 36(7):1896–1902PubMedCrossRef
7.
Liu H-T, Chancellor MB, Kuo H-C (2009) Urinary nerve growth factor levels are elevated in patients with detrusor overactivity and decreased in responders to detrusor botulinum toxin-A injection. Eur Urol 56(4):700–706PubMedCrossRef
8.
Yamauchi H, Akino H, Ito H, Aoki Y, Nomura T, Yokoyama O (2010) Urinary prostaglandin E2 was increased in patients with suprapontine brain diseases, and associated with overactive bladder syndrome. Urology 76(5):1267.e13–1267.e19CrossRef
9.
Owens T (2003) The enigma of multiple sclerosis: inflammation and neurodegeneration cause heterogeneous dysfunction and damage. Curr Opin Neurol 16(3):259–265PubMedCrossRef
10.
Neuhaus O, Archelos JJ, Hartung H-P (2003) Immunomodulation in multiple sclerosis: from immunosuppression to neuroprotection. Trends Pharmacol Sci 24(3):131–138PubMedCrossRef
11.
Caggiula M, Batocchi AP, Frisullo G, Angelucci F, Patanella AK, Sancricca C et al (2005) Neurotrophic factors and clinical recovery in relapsing-remitting multiple sclerosis. Scand J Immunol 62(2):176–182PubMedCrossRef
12.
Hohlfeld R, Kerschensteiner M, Stadelmann C, Lassmann H, Wekerle H (2006) The neuroprotective effect of inflammation: implications for the therapy of multiple sclerosis. Neurol Sci 27(Suppl 1):S1–S7PubMedCrossRef
13.
Kalinowska-Lyszczarz A, Losy J (2012) The role of neurotrophins in multiple sclerosis—pathological and clinical implications. Int J Mol Sci 13(12):13713–13725PubMedPubMedCentralCrossRef
14.
Kerschensteiner M, Stadelmann C, Dechant G, Wekerle H, Hohlfeld R (2003) Neurotrophic cross-talk between the nervous and immune systems: implications for neurological diseases. Ann Neurol 53(3):292–304PubMedCrossRef
15.
Bazhenov IV, Filippova ES, Bazarnyi VV, Sazonov SV, Volkova LI, Zaitseva LN (2019) Sensitivity and specificity of urinary and serum neurotrophins in the diagnosis of neurogenic detrusor overactivity in multiple sclerosis. Urol Mosc Russ 1999 3:44–48
16.
Şekerci ÇA, Işbilen B, Işman F, Akbal C, Şimşek F, Tarcan T (2014) Urinary NGF, TGF-β1, TIMP-2 and bladder wall thickness predict neurourological findings in children with myelodysplasia. J Urol 191(1):199–205PubMedCrossRef
17.
Peyronnet B, Even A, Capon G, De Seze M, Hascoet J, Biardeau X et al (2018) Intradetrusor injections of botulinum toxin A in adults with spinal dysraphism. J Urol 200(4):875–880PubMedCrossRef
18.
Fry CH, Kitney DG, Paniker J, Drake MJ, Kanai A, Andersson K-E (2018) Fibrosis and the bladder, implications for function ICI-RS 2017. Neurourol Urodyn 37(S4):S7–S12PubMedCrossRef
19.
Hipp JA, Hipp JD, Yoo JJ, Atala A, Andersson K-E (2008) Microarray analysis of bladder smooth muscle from patients with myelomeningocele. BJU Int 102(6):741–746PubMedCrossRef
20.
Beqaj SH, Donovan JL, Liu DB, Harrington DA, Alpert SA, Cheng EY (2005) Role of basic fibroblast growth factor in the neuropathic bladder phenotype. J Urol 174(4 Pt 2):1699–1703PubMedCrossRef
21.
Janzen J, Vuong PN, Bersch U, Michel D, Zaech GA (1998) Bladder tissue biopsies in spinal cord injured patients: histopathologic aspects of 61 cases. Neurourol Urodyn 17(5):525–530PubMedCrossRef
22.
Vignozzi L, Gacci M, Maggi M (2016) Lower urinary tract symptoms, benign prostatic hyperplasia and metabolic syndrome. Nat Rev Urol 13(2):108–119PubMedCrossRef
23.
Oztekin CV, Kaya-Sezginer E, Yilmaz-Oral D, Gur S (2018) Male urogenital disorders and metabolic syndrome: possible links, characteristics and potential treatment strategies. Curr Pharm Des 24(9):1019–1033PubMedCrossRef
24.
He Q, Wang Z, Liu G, Daneshgari F, MacLennan GT, Gupta S (2016) Metabolic syndrome, inflammation and lower urinary tract symptoms: possible translational links. Prostate Cancer Prostatic Dis 19(1):7–13PubMedCrossRef
25.
Fry CH, Sahai A, Vahabi B, Kanai AJ, Birder LA (2014) What is the role for biomarkers for lower urinary tract disorders? ICI-RS 2013. Neurourol Urodyn 33(5):602–605PubMedPubMedCentralCrossRef
26.
Gamper M, Moser R, Viereck V (2017) Have we been led astray by the NGF biomarker data?: accurate NGF Assay? Neurourol Urodyn 36(1):203–204PubMedCrossRef
Metadata
Title
Urinary biomarkers profiles in patients with neurogenic detrusor overactivity according to their neurological condition
Authors
Claire Richard
Claude Bendavid
Juliette Hascoet
Quentin Alimi
Zine-eddine Khene
Jacques Kerdraon
Caroline Voiry
Charlène Brochard
Guillaume Bouguen
Laurent Siproudhis
Andrea Manunta
Xavier Gamé
Benoit Peyronnet
Publication date
01-09-2020
Publisher
Springer Berlin Heidelberg
Published in
World Journal of Urology / Issue 9/2020
Print ISSN: 0724-4983
Electronic ISSN: 1433-8726
DOI
https://doi.org/10.1007/s00345-019-03016-x

Other articles of this Issue 9/2020

World Journal of Urology 9/2020 Go to the issue

Original Article

Ideal timing of indwelling catheter removal after robot-assisted radical prostatectomy with a running barbed suture technique: a prospective analysis of 425 consecutive patients

Letter to the Editor

Antibiotic prophylaxis in TURP: a prospective analysis concerning antibiotic stewardship and a potential reduction of antibiotic use in TURP

Topic Paper

Kidney regeneration approaches for translation

Correction

Correction to: Tissue engineering of the urethra: where are we in 2019?

Original Article

Safety and efficacy of Tamsulosin as medical expulsive therapy in pregnancy

Original Article

Development and internal validation of a nomogram to predict perioperative complications after flexible ureteroscopy for renal stones in overnight ureteral catheterization cases